People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Liquidia Technologies Inc | — | Biotechnology | Series B | $86.7M | $890.0M | 2009 |
| Trevena Inc | — | Pharmaceuticals | Series C | $77.5M | $2.1B | 2010 |
| XDx, Inc. | — | Biotechnology | Series B | $44.5M | $879.9M | 2010 |
| Proventys, Inc | — | Other | Seed | $3.3M | $60.4M | 2010 |
Ralph Snyderman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ralph Snyderman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| G. Steven Burrill | 2 | 7 |
| Stephen Bloch | 1 | 15 |
| Brook Byers | 1 | 13 |
| Fred Cohen | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Michael Goldberg | 1 | 11 |
| Isaac Cheng | 1 | 9 |
| David Solomon | 1 | 8 |
| Vijay Lathi | 1 | 8 |
| Robert Garland | 1 | 7 |
| Christopher Mirabelli | 1 | 6 |
| Seth Rudnick | 1 | 5 |
| Farah Champsi | 1 | 5 |
| Joseph DeSimone | 1 | 5 |
| Steve Nelson | 1 | 4 |
| Maxine Gowen | 1 | 4 |
| Neal Fowler | 1 | 4 |
| William Hagstrom | 1 | 4 |
| Seth A. Rudnick | 1 | 3 |
| Peter Altman | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.